Joseph Pierre Aboumsallem: ET Treatment Enters a New Chapter
Joseph Pierre Aboumsallem, Drug Development Lead – siRNA Therapeutics, Postdoctoral Researcher, Project Manager at Erasmus MC, Project Manager at University Medical Center Groningen (UMCG), shared a post on LinkedIn about a recent article by Isabelle Plo and William Vainchenker, published in NEJM, adding:
“Amazing news!!
The FDA has approved ropeginterferon alfa-2b for essential thrombocythemia (ET), the first new treatment approval for the disease in nearly 30 years.
ET is a chronic myeloproliferative neoplasm driven by clonal haematopoiesis.
Persistent thrombocytosis increases the risk of thrombosis and bleeding, and treatment options remain limited for patients who do not respond to or cannot tolerate hydroxyurea.
In SURPASS-ET, 37.4% of patients treated with ropeginterferon achieved a durable composite response, including blood count control, no progression of splenomegaly, and no thrombotic or haemorrhagic events, sustained at 9 and 12 months. The corresponding rate with anagrelide was 3.6%.
The molecular responses across JAK2, CALR and MPL are also important. Controlling platelet counts is one part of treatment.
Reducing the burden of the underlying clone is a different proposition and has been a long-standing goal in MPN research.
It is good to see interferon biology, developed over decades, now translating into a new treatment option for patients with ET.”
Title: Myeloproliferative Neoplasms
Authors: Isabelle Plo, William Vainchenker
Stay updated with Hemostasis Today.
-
Oct 10, 2026, 17:58Archo Farzana Batool: Exploring Medical Writing Through an Article on Iron Deficiency Anemia
-
Oct 10, 2026, 17:53Assessing Frailty in Adults With Hemophilia – JTH
-
Oct 10, 2026, 17:52Fatma Sadeghi: Reducing Maternal Health Inequalities Through Nursing Advocacy
-
Oct 10, 2026, 17:50Grzegorz Hensler: How Apheresis Transformed Blood Cell Separation and Collection
-
Oct 10, 2026, 17:47Hemant K Sharma: Japan’s Universal Artificial Blood Research – A Potential Breakthrough in Transfusion Medicine
-
Oct 10, 2026, 17:40John Strouse: Learning About Bleeding Disorders and Sickle Cell Disease at FWGBD
-
Oct 10, 2026, 17:34Mae Caime: Speaking at the Annual Women’s Retreat for the Hemophilia Community in Florida
-
Oct 10, 2026, 17:30Chokri Ben Lamine: PNH beyond the Textbook Triad
-
Oct 10, 2026, 17:29Ruah Alyamany: Thrombosis and Anticoagulation in Hematological Malignancies at SOHO KSA 2026